Norethindrone Acetate: The Definitive Guide

What is norethindrone acetate?

Norethindrone acetate (NETA), also called norethisterone acetate, is a prescription synthetic progestogen. A progestogen is a medicine acting like progesterone at its receptors; it can oppose estrogen’s growth-promoting effect on the endometrium, the lining inside the uterus. In menopausal hormone replacement therapy (HRT), NETA is best understood by the actual product: an approved estrogen/NETA combination is different from a standalone 5 mg tablet. [1], [2], [11]

NETA is the acetate ester of norethindrone, which the body forms after processing it. Norethindrone and norethisterone are regional names for the same base molecule, but a 0.35 mg norethindrone contraceptive pill is not a 5 mg acetate tablet or an estrogen/NETA HRT product. Distinguish name, salt/ester, strength and indication before comparing someone’s dose. [1], [3], [12]

Its principal menopausal role is the progestogen part of the pair, not a promise of independent hot-flash or sleep relief. A person can tolerate NETA better than progesterone or worse; neither “synthetic” nor “bioidentical” decides that response in advance. [2], [9], [10]

Typical Norethindrone Acetate Protocols

The ordinary approved menopausal pattern is one complete fixed-combination tablet daily or one combination patch replaced on its product schedule. Adjustment considers both hormone amounts, symptoms, bleeding, missed exposures and tolerability. The sequential patch still supplies estrogen throughout the 28-day course. A milligram (mg) is medicine amount; a daily patch release rate is not the amount placed on the skin. These are labeled combinations, not a dose-finding instruction for standalone NETA. [1], [2], [11]

What are the combination and standalone products used for?

Activella and CombiPatch are approved US estrogen/NETA menopausal products. Their intended combinations address vasomotor symptoms, hot flashes and night sweats, while the progestogen reduces estrogen-driven lining changes. The exact indications vary: Activella’s isolated vulvar/vaginal indication uses its 1/0.5 strength, and labels advise considering a local vaginal product when that is the only treatment goal. [2], [11]

The reviewed standalone 5 mg generic label instead lists secondary amenorrhea, endometriosis and abnormal uterine bleeding from hormonal imbalance without structural pathology. It explicitly says the product is not intended/recommended/approved with concomitant estrogen for endometrial protection in postmenopausal women. A clinician’s off-label use does not rewrite that product label, and the combination’s smaller NETA amount does not supply a universal quarter-tablet prescription. [1], [2]

For clarity, the standalone amenorrhea/bleeding course is 2.5–10 mg daily for 5–10 days; the endometriosis regimen starts 5 mg daily with source-described escalation. These are separate gynecologic indications, not HRT rows above or contraceptive assurance. Suppression of bleeding is also not proof that a medicine prevents pregnancy. [1]

Why is a5mg tablet different from a0.1mg combination?

The amounts belong to different medicines and goals. A fixed Activella tablet supplies a studied amount of estrogen and NETA together. A standalone 5 mg tablet was labeled for gynecologic treatment. The 2000 dose-finding trial studied estradiol 1 mg with NETA 0.1/0.25/0.5 mg; the marketed low Activella strength supplies estradiol 0.5 mg with NETA 0.1 mg. Matching the NETA number alone loses the paired estrogen and the evidence population. [1], [2], [7]

BMS guidance often names norethisterone, including standalone UK preparations and progestogen-only contraceptive tablets used off-label. Those rows should not silently become USNETA5 mg instructions. Higher estrogen, missed days, bleeding and tolerability require a full-regimen review. A forum’s lower-dose reassurance or an AI conversion is not an endometrial-protection assessment. [3], [4], [9]

How do oral tablets and CombiPatch differ?

Oral means swallowed. Transdermal means absorbed through the skin. CombiPatch contains both estradiol and NETA, releasing named daily amounts while one patch remains in place between replacements. “0.14 mg/day” is a delivery rate; it is not an instruction to swallow 0.14 mg, apply a fraction of a patch or change the patch every day. One patch is applied to the lower abdomen and replaced twice weekly, every 3–4 days, according to its label. [11]

The labeled sequential option uses estradiol-only patches for the first 14 days and CombiPatch for the last 14 days of each 28-day cycle. Estrogen continues in both phases; the progestogen is delivered during the combined phase between patch changes. If a patch falls off, the label permits reapplication or replacement while preserving the original schedule. Skin irritation or adhesion problems should be discussed without doubling patch count. [11]

Approved synthetic progestogen patch evidence is distinct from compounded progesterone cream, which does not reliably provide equivalent protection. A transdermal route does not erase all estrogen/progestogen warnings or justify substitution without checking the specific formulation. [3], [11]

How should these products be stored?

The reviewed standalone tablet label uses 20–25°C storage with permitted 15–30°C excursions; Activella also requires its exact container/storage directions. CombiPatch has a different rule: the reviewed label says refrigerate at 2–8°C and keep systems in sealed foil pouches, away from extreme temperatures. A tablet’s room-temperature rule cannot be transferred to this patch. Follow the current dispensed pack and pharmacist instructions. [1], [2], [11]

Keep medicines away from children and identify the expiry. A used patch can retain hormone; follow its disposal instructions to avoid accidental exposure. If a supply interruption affects the combined product, ask how the full protection plan will be maintained rather than continuing an estrogen-only product without reviewing the missing component. [3], [11]

What does the human evidence establish?

A 2000 randomized trial assigned 1176 healthy postmenopausal women without endometrial abnormalities to 12 months of estradiol 1 mg alone or estradiol 1 mg with continuous NETA 0.1, 0.25 or 0.5 mg. Hyperplasia, excess lining growth, occurred in 14.6% with estrogen alone versus 0.8%, 0.4% and 0.4% in the respective combinations. The published abstract does not provide verified per-arm evaluable denominators here, so the figure reports percentages and the overall trial size rather than inventing counts. [7]

This provides direct first-year protection evidence for those specific combinations. It does not establish an adequate NETA amount with any estrogen dose, prove cancer prevention, authorize a 5 mg-tablet split, or make every transdermal/oral pair equivalent. The marketed product’s own studies and label remain important. [2], [7], [11]

A 2007 pharmacokinetic study investigated 20 regularly menstruating premenopausal women given NETA 10, 20 or 40 mg daily for seven days. It showed conversion to ethinyl estradiol, a potent synthetic estrogen, at these higher doses. That is not a low-dose postmenopausal clinical-outcome trial. We do not convert the 0.1 mg in Activella into an assumed contraceptive estrogen dose, or claim that a patch eliminates this pathway. [8]

WHI’s major randomized combined trial used conjugated estrogen with medroxyprogesterone acetate, not NETA. It cannot directly rank NETA against micronized progesterone or quantify every NETA combination’s cancer/clot risk. NICE’s current caution about comparative progestogen breast-risk certainty still matters. See the WHI guide for broader context. [2], [5]

How is the acetate processed?

The body rapidly removes the acetate group, producing norethindrone. The active progestogen signal changes the estrogen-stimulated lining toward a secretory pattern rather than continuing growth alone. The molecule also has effects unlike ovarian progesterone; the smaller milligram amount does not represent a weaker version of the same capsule. [1], [2]

Its higher-dose conversion to ethinyl estradiol is a pharmacology finding, not a reason to self-calculate a combined-pill equivalent. Route, dose, estrogen co-treatment and population remain relevant. Nor should the micronized-progesterone sleep evidence be copied to NETA: improvement with a combined product may reflect night-sweat relief or another change, while depression, nausea or sleep problems can occur as unwanted effects. [1], [2], [8]

What risks should be reviewed?

Bleeding changes, headache, breast tenderness, nausea, bloating and mood effects are important tolerability questions. The standalone label contraindicates pregnancy, unexplained bleeding, breast cancer, current/history of venous or arterial clot events, impaired liver function and hypersensitivity. It recommends attention to depression history and recurrence. Severe mood deterioration or thoughts of self-harm require prompt help. [1]

The estrogen/NETA products carry their own combined-therapy warnings and restrictions. Do not infer that a transdermal formulation has no clot or cancer risk, or that all quoted WHI estimates were measured with NETA. Sudden breathlessness, chest pain, one-sided weakness, severe new headache or concerning visual symptoms need urgent assessment. Ordinary early spotting should not become an excuse to ignore heavy or persistent bleeding. [2], [6], [11]

Interactions and monitoring should follow the actual combination. For example, estrogen-containing Activella’s thyroid-hormone discussion is not a universal instruction to check every standalone NETA user’s thyroid or INR. Bring the whole medicine/supplement list to the pharmacist, particularly seizure medicines or metabolism-altering products. Higher-dose conversion research also does not establish a numerical clot-risk correction at HRT doses. [1], [2], [8]

The retrieved labels do not support adding the high-dose MPA meningioma restriction as though it were a NETA-specific contraindication. Absence of that named warning is not proof of zero risk. Where cancer, liver disease, pregnancy, prior clots or complex surgical histories are relevant, a product-specific clinical plan is needed. [1], [2], [11]

What should be checked at a refill or across borders?

Ask for the full generic name, ester, strength and whether the medicine includes estrogen. “Norethindrone” can refer to a contraceptive base-molecule pill, a therapeutic acetate tablet or an ingredient in a menopausal combination. AUKnorethisterone guideline row does not make each USacetate product licensed for that purpose. The current USstandalone and combination labels are deliberately separated here. [1], [2], [3], [11]

Approval is different from current stock, reimbursement or clinical suitability. This guide does not certify every regional brand or a live pharmacy supply. If substituting after a shortage, the pharmacist and prescriber should preserve the intended hormone pair, route and exposure days. Fixed tablets and combination patches cannot be substituted by matching only one printed number.

What do public users ask about?

A 2025 public thread asks whether a prescribed 5 mg acetate amount is too high after progesterone was poorly tolerated. Replies discuss smaller tablet amounts and following up. The practical need is a complete-prescription explanation; neither anAI reassurance nor another person’s tablet fraction establishes uterine protection with a particular patch. [9]

A 2026 discussion includes a history of acceptable tolerance while treating heavy perimenopausal bleeding, difficult grogginess after switching to progesterone, and another account of nausea that improved after a change. Estrogen additions, bleeding treatment and surgery complicate attribution. These selected narratives show both favorable and unwanted experiences; they do not prove that the progestogen alone caused later improvement. [10]

We retain no names or identifiable histories. The checked public search text is not a population survey, full clinical record or safe-dose directory. It is useful for preparing questions about the exact acetate product, the estrogen pair, mood, nausea and missed protection days. A report that bleeding stopped is not contraceptive or tissue-safety evidence. [9], [10]

What should be monitored?

Keep the whole prescription visible: the estrogen product and amount, this progestogen’s product and route, the actual exposure days, and any missed doses or refill gaps. A record that says only “one hormone pill” loses the distinction between estrogen-only days and combined days. Bleeding dates, amount, sleep, mood and effects on daily activity help the review. They do not prove that the lining is protected. [3], [5], [6]

NICE recommends a review three months after starting treatment, then annually, with earlier review when treatment is ineffective, unwanted effects are troublesome or an adverse event occurs. An adverse event is an unwanted event during treatment; it is not automatically caused by the medicine. Review may change the product, estrogen exposure, progestogen amount, route or calendar. It also considers whether the treatment remains useful for the person’s current goals. [5]

Unscheduled bleeding should be reported rather than interpreted from a hormone blood test. NICE’s April 2026 update says bleeding is common during the first six months of systemic HRT or within three months of a change, and recommends prompt medical help beyond those periods. That is not an instruction to wait with heavy, prolonged, persistent or concerning bleeding. The British pathway assesses risk factors, adherence and both hormone components, and can arrange earlier ultrasound or tissue assessment. [5], [6]

A planned withdrawal bleed after a sequential course differs from bleeding between expected courses, or new bleeding after a stable interval without it. Ultrasound assesses the lining’s thickness; a biopsy takes a tissue sample. Neither a comfortable mood nor bleeding stopping after a dose change rules out disease by itself. Keep routine breast and cervical screening appropriate to local guidance and personal risk, and report new breast changes. The purpose of follow-up is clinical assessment, not finding a universally “optimal” progesterone blood level. [3], [5], [6]

What happens when treatment stops?

Stopping the whole HRT regimen and stopping only its progestogen are different decisions. If systemic estrogen continues with a uterus present, a protection plan is still needed. Planned off-days in a sequential prescription are part of that plan; extending them because the capsule or tablet is troublesome is a treatment change. Contact the prescriber to review a suitable alternative instead of quietly removing one component. [3], [5]

Symptoms can return after stopping HRT. NICE allows either gradual reduction or immediate stopping; gradual reduction may limit symptom recurrence in the short term, but makes no long-term difference. There is no universal tablet-cutting schedule in this guidance. A fixed combination changes both hormones when it is reduced or stopped, while separate products can be adjusted independently under clinical supervision. A scored line does not always mean a tablet is authorized to provide equal smaller doses. [5]

New severe mood deterioration, major impairment or suspected serious adverse effects need prompt help, not completion of an online “adjustment period.” A clinician may stop or change treatment urgently while arranging continuing protection where needed. Record the last actual dose and what estrogen was continued; those details make a review more useful than a general report that “the hormones did not suit me.” [3], [5], [6]

How does it compare with other options?

Micronized progesterone, medroxyprogesterone acetate, norethindrone acetate, dydrogesterone and a 52 mg levonorgestrel intrauterine system are different protection options. “Progestogen” names the family; “progestin” commonly describes a synthetic member. Capsule or tablet milligrams do not measure the same potency across these molecules. The amount is interpreted with its product, estrogen exposure and treatment days. The levonorgestrel device’s HRT protection duration is separate from its contraceptive duration. [3], [4]

Tolerability matters alongside protection. Someone who feels groggy on micronized progesterone may do differently on a synthetic progestogen, while another person has the opposite experience. A fixed estrogen/progestogen product can simplify taking the intended pair, but provides less independent adjustment than separate medicines. No comparison justifies transferring one molecule’s dose to another, or assuming a contraceptive pill supplies the intended HRT opposition. [3], [4]

Breast-cancer comparisons also require care. NICE says evidence is insufficient to establish whether the increase in risk with micronized progesterone or dydrogesterone differs from other progestogens. Observational associations can inform a discussion without proving a safer drug for every person. Personal cancer history, duration, estrogen route and the exact combination remain part of the clinical review. [5]

Common questions

Can I quarter the5mg tablet forHRT?

The reviewed standalone label does not establish a quarter-tablet HRT regimen with added estrogen. A scored tablet and an approved low-dose combination are different products. Dose accuracy, estrogen exposure and protection days need a specific prescription; do not calculate a regimen from the combination’s NETA strength alone. See product differences. [1], [2], [3] Keep the exact route, formulation and clinical purpose visible. Sharing a molecule does not establish equivalent daily exposure or the same prescribing indication. See protocols. [1]

Is it the same as the mini-pill?

No. A 0.35 mg norethindrone contraceptive pill contains the base molecule and has its own regimen. NETA 5 mg is an acetate tablet for different gynecologic indications, and menopausal combinations include estrogen in specific amounts. Stopping periods does not establish contraceptive protection. Keep the exact generic, ester and purpose visible. See what it is. [1], [2], [3] Keep the exact route, formulation and clinical purpose visible. Sharing a molecule does not establish equivalent daily exposure or the same prescribing indication. See protocols. [1]

Can I compare its milligrams with progesterone?

No. These are different molecules and products, with different potency, metabolism and studied regimens. A smaller milligram number does not mean less protection or fewer adverse effects. Use the exact product-and-estrogen row, not a mass ratio or a forum conversion. The prescriber considers exposure days and estrogen dose as well as the amount. See protocols and comparisons. [3], [4] Keep the exact route, formulation and clinical purpose visible. Sharing a molecule does not establish equivalent daily exposure or the same prescribing indication. See protocols. [1]

Does no bleeding prove the lining is protected?

No. Bleeding patterns help assess a regimen, but are not a tissue-protection test. Missed exposure days, estrogen changes and the route can alter the protection question even when symptoms feel better. New or persistent unscheduled bleeding also needs assessment rather than self-adjustment. Keep the complete calendar and product information available at review. See monitoring. [3], [5], [6] Keep the exact route, formulation and clinical purpose visible. Sharing a molecule does not establish equivalent daily exposure or the same prescribing indication. See protocols. [1]

Can I stop just the progestogen?

If systemic estrogen continues with a uterus present, the protection plan still matters. Planned sequential off-days are different from an unplanned prolonged gap. Trouble tolerating treatment is a reason to review the product, route or entire regimen; it is not proof that protection can be dropped. Stopping all HRT may be gradual or immediate under NICE guidance. See stopping. [3], [5]

How long should I wait with unwanted effects?

There is no mandatory forum adjustment deadline. NICE recommends earlier review for troublesome effects or ineffective treatment, rather than waiting for the annual visit. Severe impairment, major mood deterioration or concerning bleeding needs prompt assessment. Some effects change with time, but improvement cannot be promised from selected posts. Record what changed and when, including the paired estrogen and actual dose days. See risks and monitoring. [5], [6]

Glossary

Terms used to read the product and evidence.

Adverse event

An unwanted event during treatment; it is not automatically caused by the medicine.

Amenorrhea

Absence of menstrual periods. Secondary amenorrhea occurs after periods have previously occurred.

Bioavailability

The amount of an administered medicine reaching the circulation; formulation and route can change it.

Bioidentical

Chemically identical to a hormone the body makes; the word does not establish safety or product quality.

Biopsy

A tissue sample examined for abnormalities, unlike an ultrasound measurement of thickness.

Boxed warning

A prominent warning format used in a medicine label; removing the box does not remove every risk.

Compounding

Preparing a medicine to a prescription rather than supplying a standard approved finished product.

Continuous combined HRT

Estrogen and progestogen used continuously according to their prescriptions, without scheduled progestogen-free days.

Contraindication

A condition in which a particular product must not be used under its label.

Cycle

A repeating treatment calendar. A 28-day cycle and a calendar month have different lengths.

Daily total

All doses taken on one day added together, not the average across days without treatment.

Endometrium

The lining inside the uterus that can grow in response to estrogen.

Estrogen

A family of hormones including estradiol; systemic treatment and low-dose local treatment have different purposes.

Excipient

An ingredient other than the active medicine, such as a capsule oil or lecithin.

First-pass metabolism

Processing in the intestine and liver before an oral medicine reaches the wider circulation.

Hormone replacement therapy (HRT)

In this guide, hormone treatment for menopause-related needs; also called menopausal hormone therapy.

Hyperplasia

Excessive tissue growth. Endometrial hyperplasia is not the same diagnosis as endometrial cancer.

Hysterectomy

Surgery removing the uterus; removal of ovaries is a different procedure.

Intrauterine device (IUD)

A device placed inside the uterus. Protection duration in HRT can differ from contraception duration.

Metabolite

A substance produced as the body processes another substance. Some progesterone metabolites affect brain signaling.

Micronization

Making particles smaller to change their dissolution and absorption, without changing the hormone molecule.

Milligram (mg)

A unit of mass; a 100 mg capsule contains 100 milligrams of active progesterone.

Observational study

A study following treatment choices rather than randomly assigning them; confounding can affect comparisons.

Off-label

Use outside a product’s authorized indication, route or schedule; it can be guideline-supported without becoming labeled use.

Oral

Swallowed, passing through the digestive system.

Perimenopause

The transition toward menopause, when periods and hormone patterns can change.

Placebo

A comparison treatment without the tested active medicine.

Postmenopause

The stage after menopause; context and other hormonal treatments matter when identifying it.

Progestogen

The broader family of progesterone-like medicines, including progesterone and synthetic progestins.

Randomized controlled trial

A study assigning participants to groups by chance to make a treatment comparison.

Sequential HRT

A regimen giving progestogen on selected days of a repeating cycle.

Systemic

Reaching the wider body through the circulation, rather than being intended mainly for a local site.

Transdermal

Absorbed through the skin, as with an estrogen patch; evidence for progesterone cream is different.

Vaginal

Administered in the vagina; the route alone does not establish systemic exposure or uterine protection.

Vasomotor symptoms

Hot flashes and night sweats.

Withdrawal bleeding

Bleeding following removal of hormonal exposure, such as after a sequential progesterone course.

Meningioma

A tumor arising from membranes around the brain and spinal cord; often benign, but its location can have serious effects.

How this guide was researched

We compared current product information with May/August 2026 BMS guidance and NICE, then checked original human research and relevant public discussions. Each amount retains its product, route, indication and country. A listing or page update is not necessarily a prescribing-information revision.

The directory distinguishes full text, abstracts and public search excerpts. Combination results do not prove the progestogen’s independent effect. Discussions show selected experiences, not surveys, response rates or prescribing authority. Anatomy images are conceptual; data figures use the exact values from named sources.

This educational content does not replace a prescription or clinical assessment. Sources that can change require an updated check when making a new treatment decision.

Explore the sources